The ventricular arrhythmia Torsades de Pointes (TdP) is a common form of drug‐induced
cardiotoxicity, but prediction of this arrhythmia remains an unresolved issue in drug …

Torsade de Pointes (TdP), a rare but lethal ventricular arrhythmia, is a toxic side effect of
many drugs. To assess TdP risk, safety regulatory guidelines require quantification of hERG …

In silico cardiac myocyte models present powerful tools for drug safety testing and for
predicting phenotypical consequences of ion channel mutations, but their accuracy is …

Torsades de Pointes (TdP) is a type of ventricular arrhythmia which could be observed as an
unwanted drug-induced cardiac side effect, and it is associated with repolarization …

Drug-induced torsade de pointes (TdP) is a life-threatening ventricular arrhythmia
responsible for the withdrawal of many drugs from the market. Although currently used TdP …

Drug-induced Torsade-de-Pointes (TdP) has been responsible for the withdrawal of many
drugs from the market and is therefore of major concern to global regulatory agencies and …

While pre-clinical Torsades de Pointes (TdP) risk classifiers had initially been based on drug-
induced block of hERG potassium channels, it is now well established that improved risk …

Aims The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one
of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de …

Rationale: Drug-induced proarrhythmia is so tightly associated with prolongation of the QT
interval that QT prolongation is an accepted surrogate marker for arrhythmia. But QT interval …

Torsades de pointes (TdP) is a malignant polymorphic ventricular tachyarrhythmia that can
be caused by drugs that induce electrophysiological changes. Although the number of drugs …